Compare Coinbase Global, Inc. (COIN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs Sanofi SA — how do they compare? Coinbase Global, Inc. trades at $148.41 (market cap $39.20B), while Sanofi SA trades at $43.59 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 2.7× Coinbase Global, Inc.'s market cap, and Sanofi SA pays a 5.55% dividend while Coinbase Global, Inc. pays none. Which is the better fit depends on your goals.
| COIN | SNY | |
|---|---|---|
Market Cap | $39.20B | $104.30B |
Sector | Technology | Health |
52-Week High | $387.27 | $52.34 |
52-Week Low | $141.09 | $41.33 |
Enterprise Value | $36.85B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COIN trades at $148.4, down 0.19% with a bearish technical signal. Recent earnings misses and a net loss in Q2 2026 highlight challenges despite revenue growth. The stock faces pressure from a sluggish crypto market, but maintains strong cash flow and a 55% analyst buy rating with a $207.20 price target.
Outlook remains mixed: strong fundamentals like positive EBITDA and cash flow support long-term potential, but near-term risks from earnings volatility and market sentiment weigh on performance. Investors should balance growth prospects against sector headwinds.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
